LYMPDAC

Here, the aim is to make a crossroad of mechanobiology and cellular biology to target PDAC. By inducing PDAC intratumoural formation of LVs a lower IFP will be achieved. This new mechanoenvironment will favour the delivery of chemo and angio/immunotherapies. This objective will be achieved by using a new and innovative technique, the use of microfluidic devices together with a robust in vivo mouse model of PDAC.

This study will be vital for advancing the fundamental understanding of the complex PDAC tumor microenvironment and will open new avenues to make effective therapies for PDAC patients. Importantly, the combination of biomechanics and cancer cell biology will entail new horizons for cancer therapeutics. Moreover, given the existence of organ-specific vascular organization, the modulation of LVs in a solid tumor different to subcutaneous melanoma or breast cancer models is a challenge nowadays and will uncover clinically relevant outputs.